Resistance in gram-negative bacteria: Enterobacteriaceae

2004, National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004, Am J Infect Control, 32, 470, 10.1016/j.ajic.2004.10.001 Paterson, 2004, International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections, Ann Intern Med, 140, 26, 10.7326/0003-4819-140-1-200401060-00008 Rupp, 2003, Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention, and drug treatment, Drugs, 63, 353, 10.2165/00003495-200363040-00002 Shah, 2004, Extended-spectrum beta-lactamases (ESBLs): characterization, epidemiology, and detection, Crit Rev Microbiol, 30, 25, 10.1080/10408410490266429 Kollef, 1999, Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients, Chest, 115, 462, 10.1378/chest.115.2.462 Du, 2002, Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome, Intensive Care Med, 28, 1718, 10.1007/s00134-002-1521-1 Paterson, 2004, Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases, Clin Infect Dis, 39, 31, 10.1086/420816 Bradford, 2001, Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat, Clin Microbiol Rev, 14, 933, 10.1128/CMR.14.4.933-951.2001 Walther-Rasmussen, 2004, Cefotaximases (CTX-M-ases), an expanding family of extended-spectrum beta-lactamases, Can J Microbiol, 50, 137, 10.1139/w03-111 Jacoby, 2005, The new beta-lactamases, N Engl J Med, 352, 380, 10.1056/NEJMra041359 Walsh, 2005, Metallo-beta-lactamases: the quiet before the storm?, Clin Microbiol Rev, 18, 306, 10.1128/CMR.18.2.306-325.2005 Thomson, 2001, Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae, Antimicrob Agents Chemother, 45, 3548, 10.1128/AAC.45.12.3548-3554.2001 Jett, 1995, In vitro activities of various beta-lactam antimicrobial agents against clinical isolates of Escherichia coli and Klebsiella spp. resistant to oxyimino cephalosporins, Antimicrob Agents Chemother, 39, 1187, 10.1128/AAC.39.5.1187 Paterson, 2001, Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory, J Clin Microbiol, 39, 2206, 10.1128/JCM.39.6.2206-2212.2001 Wong-Beringer, 2002, Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime, Clin Infect Dis, 34, 135, 10.1086/324742 2005 Zanetti, 2003, Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study, Antimicrob Agents Chemother, 47, 3442, 10.1128/AAC.47.11.3442-3447.2003 Alvarez, 2004, Epidemiology of conjugative plasmid-mediated AmpC beta-lactamases in the United States, Antimicrob Agents Chemother, 48, 533, 10.1128/AAC.48.2.533-537.2004 Tracz, 2005, Increase in AmpC promoter strength due to mutations and deletion of the attenuator in a clinical isolate of cefoxitin-resistant Escherichia coli as determined by RT-PCR, J Antimicrob Chemother, 55, 768, 10.1093/jac/dki074 Martinez-Martinez, 1996, In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum-cephalosporins, Antimicrob Agents Chemother, 40, 342, 10.1128/AAC.40.2.342 Lautenbach, 2001, Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae, Clin Infect Dis, 33, 1288, 10.1086/322667 DiPersio, 2005, Evolution and dissemination of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae: epidemiology and molecular report from the SENTRY Antimicrobial Surveillance Program (1997–2003), Diagn Microbiol Infect Dis, 51, 1, 10.1016/j.diagmicrobio.2004.08.001 Hyle, 2005, Risk factors for increasing multidrug resistance among extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species, Clin Infect Dis, 40, 1317, 10.1086/429239 Pitout, 2005, Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community, J Antimicrob Chemother, 56, 52, 10.1093/jac/dki166 Pitout, 2004, Population-based laboratory surveillance for Escherichia coli-producing extended-spectrum beta-lactamases: importance of community isolates with blaCTX-M genes, Clin Infect Dis, 38, 1736, 10.1086/421094 Moland, 2003, Discovery of CTX-M-like extended-spectrum beta-lactamases in Escherichia coli isolates from 5 US States, Antimicrob Agents Chemother, 47, 2382, 10.1128/AAC.47.7.2382-2383.2003 Paterson, 2003, Extended-spectrum beta-lactamases in Klebsiella pneumoniae bloodstream isolates from 7 countries: dominance and widespread prevalence of SHV- and CTX-M-type beta-lactamases, Antimicrob Agents Chemother, 47, 3554, 10.1128/AAC.47.11.3554-3560.2003 Colodner, 2004, Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients, Eur J Clin Microbiol Infect Dis, 23, 163, 10.1007/s10096-003-1084-2 Munday, 2004, Predominance and genetic diversity of community- and hospital-acquired CTX-M extended-spectrum beta-lactamases in York, UK, J Antimicrob Chemother, 54, 628, 10.1093/jac/dkh397 Rodriguez-Bano, 2004, Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients, J Clin Microbiol, 42, 1089, 10.1128/JCM.42.3.1089-1094.2004 Woodford, 2004, Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK, J Antimicrob Chemother, 54, 735, 10.1093/jac/dkh424 Kruger, 2004, Infections with nontyphoidal Salmonella species producing TEM-63 or a novel TEM enzyme, TEM-131, in South Africa, Antimicrob Agents Chemother, 48, 4263, 10.1128/AAC.48.11.4263-4270.2004 Ishii, 2005, Extended-spectrum beta-lactamase-producing Shiga toxin gene (Stx1)-positive Escherichia coli O26:H11: a new concern, J Clin Microbiol, 43, 1072, 10.1128/JCM.43.3.1072-1075.2005 Kim, 2004, Occurrence of extended-spectrum beta-lactamases in members of the genus Shigella in the Republic of Korea, J Clin Microbiol, 42, 5264, 10.1128/JCM.42.11.5264-5269.2004 Petroni, 2002, Plasmidic extended-spectrum beta-lactamases in Vibrio cholerae O1 El Tor isolates in Argentina, Antimicrob Agents Chemother, 46, 1462, 10.1128/AAC.46.5.1462-1468.2002 Radice, 2001, Third-generation cephalosporin resistance in Shigella sonnei, Argentina, Emerg Infect Dis, 7, 442, 10.3201/eid0703.017313 Vignoli, 2005, Enteropathogenic Escherichia coli strains carrying genes encoding the PER-2 and TEM-116 extended-spectrum beta-lactamases isolated from children with diarrhea in Uruguay, J Clin Microbiol, 43, 2940, 10.1128/JCM.43.6.2940-2943.2005 Li, 2005, Ceftriaxone resistance of nontyphoidal Salmonella enterica isolates in Northern Taiwan attributable to production of CTX-M-14 and CMY-2 β-lactamases, J Clin Microbiol, 43, 3237, 10.1128/JCM.43.7.3237-3243.2005 Carattoli, 2002, Characterization of plasmids carrying CMY-2 from expanded-spectrum cephalosporin-resistant Salmonella strains isolated in the United States between 1996 and 1998, Antimicrob Agents Chemother, 46, 1269, 10.1128/AAC.46.5.1269-1272.2002 Dunne, 2000, Emergence of domestically acquired ceftriaxone-resistant Salmonella infections associated with AmpC beta-lactamase, JAM, 284, 3151, 10.1001/jama.284.24.3151 Fey, 2000, Ceftriaxone-resistant salmonella infection acquired by a child from cattle, N Engl J Med, 342, 1242, 10.1056/NEJM200004273421703 Bouza, 2002, Klebsiella and Enterobacter: antibiotic resistance and treatment implications, Semin Respir Infect, 17, 215, 10.1053/srin.2002.34693 Chow, 1991, Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy, Ann Intern Med, 115, 585, 10.7326/0003-4819-115-8-585 Levison, 2002, Regional occurrence of plasmid-mediated SHV-7, an extended-spectrum beta-lactamase, in Enterobacter cloacae in Philadelphia Teaching Hospitals, Clin Infect Dis, 35, 1551, 10.1086/344178 Sanders, 2002, BetalasEN: microdilution panel for identifying beta-lactamases present in isolates of Enterobacteriaceae, J Clin Microbiol, 40, 123, 10.1128/JCM.40.1.123-127.2002 D'Agata, 1998, The molecular and clinical epidemiology of Enterobacteriaceae producing extended-spectrum beta-lactamase in a tertiary care hospital, J Infect, 36, 279, 10.1016/S0163-4453(98)94171-8 Tzelepi, 2000, Detection of extended-spectrum beta-lactamases in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes, J Clin Microbiol, 38, 542, 10.1128/JCM.38.2.542-546.2000 Park, 2005, Occurrence of extended-spectrum beta-lactamases among chromosomal AmpC-producing Enterobacter cloacae, Citrobacter freundii, and Serratia marcescens in Korea and investigation of screening criteria, Diagn Microbiol Infect Dis, 51, 265, 10.1016/j.diagmicrobio.2004.11.009 Jiang, 2005, Outbreak of infection caused by Enterobacter cloacae producing the novel VEB-3 beta-lactamase in China, J Clin Microbiol, 43, 826, 10.1128/JCM.43.2.826-831.2005 Pai, 2004, High prevalence of extended-spectrum beta-lactamase-producing strains among blood isolates of Enterobacter spp. collected in a tertiary hospital during an 8-year period and their antimicrobial susceptibility patterns, Antimicrob Agents Chemother, 48, 3159, 10.1128/AAC.48.8.3159-3161.2004 Szabo, 2005, SHV-type extended-spectrum beta-lactamase production is associated with reduced cefepime susceptibility in Enterobacter cloacae, J Clin Microbiol, 43, 5058, 10.1128/JCM.43.10.5058-5064.2005 Carson, 2004, Role of fluoroquinolones in the treatment of serious bacterial urinary tract infections, Drugs, 64, 1359, 10.2165/00003495-200464120-00007 Hooper, 1998, Clinical applications of quinolones, Biochim Biophys Acta, 1400, 45, 10.1016/S0167-4781(98)00127-4 Xiong, 2002, Investigation of extended-spectrum beta-lactamase in Klebsiellae pneumoniae and Escherichia coli from China, Diagn Microbiol Infect Dis, 44, 195, 10.1016/S0732-8893(02)00441-8 Paterson, 2000, Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia, Clin Infect Dis, 30, 473, 10.1086/313719 Hooper, 1999, Mechanisms of fluoroquinolone resistance, Drug Resist Updat, 2, 38, 10.1054/drup.1998.0068 Martinez-Martinez, 1998, Quinolone resistance from a transferable plasmid, Lancet, 351, 797, 10.1016/S0140-6736(97)07322-4 Wang, 2003, Plasmid-mediated quinolone resistance in clinical isolates of Escherichia coli from Shanghai, China, Antimicrob Agents Chemother, 47, 2242, 10.1128/AAC.47.7.2242-2248.2003 Mammeri, 2005, Emergence of plasmid-mediated quinolone resistance in Escherichia coli in Europe, Antimicrob Agents Chemother, 49, 71, 10.1128/AAC.49.1.71-76.2005 Rodriguez-Martinez, 2003, Detection of the plasmid-mediated quinolone resistance determinant qnr among clinical isolates of Klebsiella pneumoniae producing AmpC-type beta-lactamase, J Antimicrob Chemother, 52, 703, 10.1093/jac/dkg388 Wang, 2004, Emerging plasmid-mediated quinolone resistance associated with the qnr gene in Klebsiella pneumoniae clinical isolates in the United States, Antimicrob Agents Chemother, 48, 1295, 10.1128/AAC.48.4.1295-1299.2004 Tran, 2002, Mechanism of plasmid-mediated quinolone resistance, Proc Natl Acad Sci U S A, 99, 5638, 10.1073/pnas.082092899 Bornet, 2000, Imipenem resistance of Enterobacter aerogenes mediated by outer membrane permeability, J Clin Microbiol, 38, 1048, 10.1128/JCM.38.3.1048-1052.2000 de Champs, 1993, Clinical and bacteriological study of nosocomial infections due to Enterobacter aerogenes resistant to imipenem, J Clin Microbiol, 31, 123, 10.1128/JCM.31.1.123-127.1993 Chow, 1991, Imipenem resistance associated with the loss of a 40 kDa outer membrane protein in Enterobacter aerogenes, J Antimicrob Chemother, 28, 499, 10.1093/jac/28.4.499 Poirel, 2004, Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae, Antimicrob Agents Chemother, 48, 15, 10.1128/AAC.48.1.15-22.2004 Martinez-Martinez, 1999, Roles of beta-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae, Antimicrob Agents Chemother, 43, 1669, 10.1128/AAC.43.7.1669 Bradford, 1997, Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the loss of an outer membrane protein, Antimicrob Agents Chemother, 41, 563, 10.1128/AAC.41.3.563 Lincopan, 2005, First isolation of metallo-beta-lactamase-producing multiresistant Klebsiella pneumoniae from a patient in Brazil, J Clin Microbiol, 43, 516, 10.1128/JCM.43.1.516-519.2005 Giakkoupi, 2003, VIM-1 Metallo-beta-lactamase-producing Klebsiella pneumoniae strains in Greek hospitals, J Clin Microbiol, 41, 3893, 10.1128/JCM.41.8.3893-3896.2003 Yan, 2001, Outbreak of infection with multidrug-resistant Klebsiella pneumoniae carrying bla(IMP-8) in a university medical center in Taiwan, J Clin Microbiol, 39, 4433, 10.1128/JCM.39.12.4433-4439.2001 Koh, 2001, Carbapenem-resistant Klebsiella pneumoniae in Singapore producing IMP-1 beta-lactamase and lacking an outer membrane protein, Antimicrob Agents Chemother, 45, 1939, 10.1128/AAC.45.6.1939-1940.2001 Galani, 2005, Characterization of a new integron containing bla(VIM-1) and aac(6′)-IIc in an Enterobacter cloacae clinical isolate from Greece, J Antimicrob Chemother, 55, 634, 10.1093/jac/dki073 Giakkoupi, 2005, Discrepancies and interpretation problems in susceptibility testing of VIM-1-producing Klebsiella pneumoniae isolates, J Clin Microbiol, 43, 494, 10.1128/JCM.43.1.494-496.2005 Yigit, 2001, Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae, Antimicrob Agents Chemother, 45, 1151, 10.1128/AAC.45.4.1151-1161.2001 Smith Moland, 2003, Plasmid-mediated, carbapenem-hydrolysing beta-lactamase, KPC-2, in Klebsiella pneumoniae isolates, J Antimicrob Chemother, 51, 711, 10.1093/jac/dkg124 Bradford, 2004, Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City, Clin Infect Dis, 39, 55, 10.1086/421495 Woodford, 2004, Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center, Antimicrob Agents Chemother, 48, 4793, 10.1128/AAC.48.12.4793-4799.2004 Bratu, 2005, Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium, Arch Intern Med, 165, 1430, 10.1001/archinte.165.12.1430 Bratu, 2005, Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection, Antimicrob Agents Chemother, 49, 3018, 10.1128/AAC.49.7.3018-3020.2005 Bratu, 2005, Detection of KPC carbapenem-hydrolyzing enzymes in Enterobacter spp. from Brooklyn, New York, Antimicrob Agents Chemother, 49, 776, 10.1128/AAC.49.2.776-778.2005 Bratu, 2005, Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents, J Antimicrob Chemother, 56, 128, 10.1093/jac/dki175 Miriagou, 2003, Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class A carbapenemase KPC-2, Antimicrob Agents Chemother, 47, 1297, 10.1128/AAC.47.4.1297-1300.2003